Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 2Genitourinary 2Dermatologic 2Breast 2Gynecologic 1

Conditions

Ovarian Neoplasms 1Melanoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 20Nivolumab 10Cyclophosphamide 10atezolizumab 6Specimen Handling 6fludarabine 5Magnetic Resonance Spectroscopy 5cabozantinib 4Ipilimumab 4Bevacizumab 4lenvatinib 3X-Rays 3Trastuzumab 3Paclitaxel 3Oxaliplatin 3Immunoglobulin G 3Fluorodeoxyglucose F18 3ulixertinib 2sargramostim 2poly ICLC 2epacadostat 2enzalutamide 2durvalumab 2cemiplimab 2budigalimab 2avelumab 2aldesleukin 2aflibercept 2Sirolimus 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × ARQ 197 × Gynecologic × Clear all
NCT01178411 2021-03-10

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Completed
60 enrolled 11 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡